Neoadjuvant ChemoRadiotherapy Followed by Immunotherapy and Surgery for Resectable Esophageal Squamous Cell Carcinoma（CRIS-2 Trial）

NCT06509568 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

92

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Squamous Cell Carcinoma

Interventions

RADIATION: Neoadjuvant chemoradiotherapy followed by immunotherapy
DRUG: Neoadjuvant chemoimmunotherapy

Sponsor

Zhejiang Cancer Hospital